GR1003359B - Λιποσωμιακο νιφλουμικο οξυ - νεο διαδερμικο αντιφλεγμονωδες φαρμακο [κεφαλη ψαροτουφεκου - Google Patents
Λιποσωμιακο νιφλουμικο οξυ - νεο διαδερμικο αντιφλεγμονωδες φαρμακο [κεφαλη ψαροτουφεκουInfo
- Publication number
- GR1003359B GR1003359B GR980100469A GR980100469A GR1003359B GR 1003359 B GR1003359 B GR 1003359B GR 980100469 A GR980100469 A GR 980100469A GR 980100469 A GR980100469 A GR 980100469A GR 1003359 B GR1003359 B GR 1003359B
- Authority
- GR
- Greece
- Prior art keywords
- encapsulated
- medecine
- liposomes
- niflumic acid
- encapsulation
- Prior art date
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 150000002632 lipids Chemical class 0.000 abstract 3
- 239000002502 liposome Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 abstract 2
- 238000005538 encapsulation Methods 0.000 abstract 2
- 229960000916 niflumic acid Drugs 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 239000000725 suspension Substances 0.000 abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 239000006071 cream Substances 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000012467 final product Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035699 permeability Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 238000007493 shaping process Methods 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται στον εγκλωβισμό του φαρμάκου Νιφλουμικό Οξύ σε λιποσώματα, για τη δημιουργία νέου διαδερμικού μη στεροειδούς αντιφλεγμονώδους σκευάσματος.Διάφορα φαρμακευτικά μόρια έχουν εγκλωβιστεί σε λιποσώματα, τα οποία είναι σφαιρικές λιπιδικές δομές, με τεχνικές όπως της ενεργούς μεταφοράς ή του εγκλωβισμού του φαρμάκου στη λιπιδική διπλοστοιβάδα. Στόχος της τεχνολογίας αυτής είναι η βελτίωση των φαρμακοκινητικών ιδιοτήτων, η αύξηση της εκλεκτικότητας των φαρμάκων ως προς τους ιστούς, καθώς και αύξηση της δερματικής διαπερατότητας.Το Νιφλουμικό οξύ καθώς και τα εστερικά του παράγωγα, εγκλωβίστηκαν σε διαφορετικής λιπιδικής σύστασης λιποσώματα με τις δύο τεχνικές που αναφέρθηκαν παραπάνω, με στόχο την αύξηση της αποτελεσματικότητας της δραστικής ουσίας.Επίσης μετρήθηκαν τα φυσικοχημικά χαρακτηριστικά του λιποσωμιακού εναιωρήματος, με ή χωρίς το εγκλωβισμένο φάρμακο όπως μέγεθος, σταθερότητα σε διαφορετικές συνθήκες φύλαξης, όσον αφορά τη θερμοκρασία και την υγρασία.Ακολούθησε η μορφοποίηση του λιποσωμιακού εναιωρήματος με ή χωρίς το εγκλωβισμένο φάρμακο σε κρέμα και μελέτη σταθερότητας της τελικής φαρμακοτεχνικής μορφής.Τέλος έγινε έλεγχος της διαπερατότητας της νθρώπου και έλεγχος της αποτελεσματικότητας αυτού in vivo σε ανθρώπους ακολουθώντας συγκεκριμένα πρωτόκολλα.ΰ
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR98100469 | 1998-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR1003359B true GR1003359B (el) | 2000-04-10 |
Family
ID=10943556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR980100469A GR1003359B (el) | 1998-12-24 | 1998-12-24 | Λιποσωμιακο νιφλουμικο οξυ - νεο διαδερμικο αντιφλεγμονωδες φαρμακο [κεφαλη ψαροτουφεκου |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1140089A1 (el) |
| JP (1) | JP2002533394A (el) |
| KR (1) | KR20010089889A (el) |
| CN (1) | CN1331592A (el) |
| AU (1) | AU1673400A (el) |
| BR (1) | BR9917006A (el) |
| CA (1) | CA2357765A1 (el) |
| CZ (1) | CZ20012240A3 (el) |
| GR (1) | GR1003359B (el) |
| HU (1) | HUP0104853A3 (el) |
| IL (1) | IL143499A0 (el) |
| IS (1) | IS5964A (el) |
| MX (1) | MXPA01006462A (el) |
| NO (1) | NO20013015D0 (el) |
| PL (1) | PL349344A1 (el) |
| SK (1) | SK7962001A3 (el) |
| WO (1) | WO2000038681A1 (el) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100367932C (zh) * | 2002-11-26 | 2008-02-13 | 吉里德科学公司 | 借助梯度的脂质体中药物装填的方法 |
| CA2523413A1 (en) | 2003-04-25 | 2004-11-11 | The Penn State Research Foundation | Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds |
| US20050255154A1 (en) | 2004-05-11 | 2005-11-17 | Lena Pereswetoff-Morath | Method and composition for treating rhinitis |
| JP4791082B2 (ja) * | 2005-05-30 | 2011-10-12 | 株式会社クラレ | リポソームおよびそれを含む皮膚外用剤 |
| JP4931369B2 (ja) * | 2005-05-31 | 2012-05-16 | ポーラ化成工業株式会社 | リポソームおよびそれを含む処置用の組成物 |
| JP5846711B2 (ja) | 2005-06-09 | 2016-01-20 | メダ アーベー | 炎症性疾患の治療のための方法及び組成物 |
| US20120028335A1 (en) | 2010-07-28 | 2012-02-02 | Life Technologies Corporation | Anti-viral azide-containing compounds |
| CN103237546B (zh) | 2010-07-28 | 2016-06-08 | 生命科技公司 | 抗病毒的含有叠氮化物的化合物 |
| EP2807252B1 (en) | 2012-01-26 | 2017-05-10 | Life Technologies Corporation | Methods for increasing the infectivity of viruses |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4528193A (en) * | 1978-12-27 | 1985-07-09 | A. Natterman & Cie. Gmbh | Inflammation-preventing pharmaceutical composition of oral administration |
| EP0225162A2 (en) * | 1985-11-27 | 1987-06-10 | Ethicon, Inc. | Inhibition of post-surgical adhesion formation by the topical administration of non-steroidal anti-inflammatory drug |
| EP0249561A2 (en) * | 1986-06-12 | 1987-12-16 | The Liposome Company, Inc. | Compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs |
| WO1996032930A1 (en) * | 1995-04-18 | 1996-10-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposome drug-loading method and composition |
-
1998
- 1998-12-24 GR GR980100469A patent/GR1003359B/el not_active IP Right Cessation
-
1999
- 1999-12-22 CZ CZ20012240A patent/CZ20012240A3/cs unknown
- 1999-12-22 KR KR1020017008144A patent/KR20010089889A/ko not_active Withdrawn
- 1999-12-22 JP JP2000590635A patent/JP2002533394A/ja active Pending
- 1999-12-22 WO PCT/GR1999/000048 patent/WO2000038681A1/en not_active Ceased
- 1999-12-22 PL PL99349344A patent/PL349344A1/xx not_active Application Discontinuation
- 1999-12-22 EP EP99959605A patent/EP1140089A1/en not_active Withdrawn
- 1999-12-22 AU AU16734/00A patent/AU1673400A/en not_active Abandoned
- 1999-12-22 SK SK796-2001A patent/SK7962001A3/sk unknown
- 1999-12-22 BR BR9917006-0A patent/BR9917006A/pt not_active Application Discontinuation
- 1999-12-22 CN CN99814948A patent/CN1331592A/zh active Pending
- 1999-12-22 MX MXPA01006462A patent/MXPA01006462A/es unknown
- 1999-12-22 HU HU0104853A patent/HUP0104853A3/hu unknown
- 1999-12-22 IL IL14349999A patent/IL143499A0/xx unknown
- 1999-12-22 CA CA002357765A patent/CA2357765A1/en not_active Abandoned
-
2001
- 2001-06-08 IS IS5964A patent/IS5964A/is unknown
- 2001-06-18 NO NO20013015A patent/NO20013015D0/no not_active Application Discontinuation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4528193A (en) * | 1978-12-27 | 1985-07-09 | A. Natterman & Cie. Gmbh | Inflammation-preventing pharmaceutical composition of oral administration |
| EP0225162A2 (en) * | 1985-11-27 | 1987-06-10 | Ethicon, Inc. | Inhibition of post-surgical adhesion formation by the topical administration of non-steroidal anti-inflammatory drug |
| EP0249561A2 (en) * | 1986-06-12 | 1987-12-16 | The Liposome Company, Inc. | Compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs |
| WO1996032930A1 (en) * | 1995-04-18 | 1996-10-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposome drug-loading method and composition |
Also Published As
| Publication number | Publication date |
|---|---|
| BR9917006A (pt) | 2001-10-30 |
| PL349344A1 (en) | 2002-07-15 |
| KR20010089889A (ko) | 2001-10-12 |
| IL143499A0 (en) | 2002-04-21 |
| HUP0104853A3 (en) | 2003-05-28 |
| MXPA01006462A (es) | 2002-06-04 |
| WO2000038681A1 (en) | 2000-07-06 |
| IS5964A (is) | 2001-06-08 |
| AU1673400A (en) | 2000-07-31 |
| SK7962001A3 (en) | 2002-02-05 |
| NO20013015L (no) | 2001-06-18 |
| JP2002533394A (ja) | 2002-10-08 |
| CA2357765A1 (en) | 2000-07-06 |
| HUP0104853A2 (hu) | 2002-05-29 |
| CZ20012240A3 (cs) | 2001-11-14 |
| CN1331592A (zh) | 2002-01-16 |
| EP1140089A1 (en) | 2001-10-10 |
| NO20013015D0 (no) | 2001-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Patel et al. | An overview of phytosomes as an advanced herbal drug delivery system | |
| Kumar et al. | A review on phytosomes: novel approach for herbal phytochemicals | |
| ES2223468T3 (es) | Complemento alimenticio y procedimiento de tratamiento cosmetico a base de un extracto de uva rico en polifenoles. | |
| US20100210572A1 (en) | Hydrolysate of crocin | |
| Rathore et al. | Planterosomes: A potential phyto-phospholipid carriers for the bioavailability enhancement of herbal extracts | |
| CN105395469A (zh) | 活性物质的冻干组合物 | |
| Udapurkar et al. | Phyto-phospholipid complex vesicles for phytoconstituents and herbal extracts: A promising drug delivery system | |
| CN104997652A (zh) | 一种抗皱保湿脂质体及其制备方法和应用 | |
| GR1003359B (el) | Λιποσωμιακο νιφλουμικο οξυ - νεο διαδερμικο αντιφλεγμονωδες φαρμακο [κεφαλη ψαροτουφεκου | |
| JP4634040B2 (ja) | リン脂質混合物、ホスホビオフラボン複合体及び該ホスホリオフラボン複合体を含む組成物 | |
| Kattyar et al. | Phytosomes and recent research on phytosomal drugs | |
| Varde et al. | Phytosomes: a potential phospholipid nanoparticulate carrier for the bioavailability enhancement of herbal extracts | |
| Poudyal et al. | A Comprehensive Review on Phytosomes: A Novel Drug Delivery System of Phytoconstituents.(2022) | |
| Ravi et al. | Phytosomes: a novel molecular nano complex between phytomolecule and phospholipid as a value added herbal drug delivery system | |
| KR101208120B1 (ko) | 비타민 복합체, 이를 제조하는 방법 및 이를 포함하는 화장료 조성물 | |
| AU2016250068B2 (en) | One-step method for production of Ultra-small Lipid Structures | |
| Singh et al. | Herbal bioactive: A booster dose for advanced pharmaceutical nanoscience | |
| Kamireddy et al. | Phytosomal Drug Delivery System: A Detailed Study | |
| BRPI1105312B1 (pt) | Composições farmacêuticas compreendendo extrato de arrabidaea chica, verlot em sistemas de liberação micro e nanoparticulados e lipossomais, processos de fabricação e uso dos mesmos | |
| Vrushabh et al. | Review on Phytosome for Topical Drug Delivery | |
| Berry et al. | PHYTOSOMES: FROM HERBAL DRUG DELIVERY TO TARGETED CLINICAL THERAPY | |
| KR101844673B1 (ko) | 그라비올라 추출물을 안정화한 니오좀을 함유하는 화장료 조성물 | |
| JP2002212071A (ja) | 経口表皮透過バリア機能改善剤 | |
| JPH0624999A (ja) | リポソーム製剤 | |
| Dwivedi et al. | PHYTOSOMES AS A DRUG DELIVERY SYSTEM: A REVIEW |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ML | Lapse due to non-payment of fees |